Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans.

@article{Kamel2010MetabolismPA,
  title={Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans.},
  author={Amin M Kamel and R Scott Obach and Kevin Colizza and Weiwei Wang and Thomas N O'Connell and Richard V Coelho and Ryan M. Kelley and Klaas Schildknegt},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2010},
  volume={38 11},
  pages={1984-99}
}
The metabolism, pharmacokinetics, and excretion of a potent and selective 5-hydroxytryptamine(1B) receptor antagonist elzasonan have been studied in six healthy male human subjects after oral administration of a single 10-mg dose of [(14)C]elzasonan. Total recovery of the administered dose was 79% with approximately 58 and 21% of the administered radioactive dose excreted in feces and urine, respectively. The average t(1/2) for elzasonan was 31.5 h. Elzasonan was extensively metabolized, and… CONTINUE READING